Roche details early obesity data from GLP-1/GIP agonist, plans for Phase 2 study this year
Roche shared additional Phase 1b data for the obesity drug it acquired in the Carmot Therapeutics deal that suggest a higher dose had yet to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
